Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Sanofi optioned the first development candidate from its multi-program collaboration with Recursion, triggering a $10 million milestone payment to Recursion. This brings total upfront and milestone payments under the collaboration to $144 million, with Recursion eligible for more than $300 million in additional milestones plus low double-digit royalties on net sales if approved.
Key figures
- Deal Value Usd
- $144 million total upfront and milestone payments to date; more than $300 million in additional milestones eligible
- Royalties
- low double-digit on net product sales
- Milestone payment
- $10 million
- Revenue recognition
- Q3 2026
- Total payments to date
- $144 million
- Additional milestones eligible
- more than $300 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.